Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

efaproxiral

Known as: 2-(4-(((3,5-dimethylanilino)carbonyl)methyl)phenoxy)-2-methylpropionic acid, 2-Dacmpp, Efaproxyn 
A synthetic small molecule with radiosensitizing activity. Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
A safe, functional-group-tolerant and high-throughput version of the trimethylaluminium mediated amide bond formation reaction… Expand
Is this relevant?
2007
2007
OBJECTIVE To determine whether efaproxiral, an allosteric modifier of hemoglobin, improves quality of life and quality of… Expand
Is this relevant?
2007
2007
Abstract Hou, H., Khan, N., Grinberg, O. Y., Yu, H., Grinberg, S. A., Lu, S., Demidenko, E., Steffen, R. P. and Swartz, H. M. The… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE To determine whether efaproxiral, an allosteric modifier of hemoglobin, improves survival in patients with brain… Expand
Is this relevant?
Review
2006
Review
2006
Opinion statementThe development of brain metastases is often viewed as the end stage of a disease course and engenders… Expand
Is this relevant?
2006
2006
PURPOSE To determine the prognostic factors for radiographic response and its prognostic value for subsequent survival in… Expand
Is this relevant?
2005
2005
PURPOSE To determine quantitatively the changes in oxygenation of intracranial tumors induced by efaproxiral, an allosteric… Expand
Is this relevant?
2005
2005
PURPOSE Efaproxiral (RSR13) reduces hemoglobin oxygen-binding affinity, facilitates oxygen release, and increases tissue pO2. We… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2004
2004
  • John H. Suh
  • Expert opinion on investigational drugs
  • 2004
  • Corpus ID: 22624281
Efaproxiral (RSR13) is a synthetic allosteric modifier of haemoglobin that reduces its oxygen binding affinity. By facilitating… Expand
Is this relevant?
2002
2002
PURPOSE The objectives of this phase II study were to determine survival, safety, pharmacokinetics (PK), and pharmacodynamics (PD… Expand
Is this relevant?